| A novel BCMA-specific, centyrin-based CAR-T product for the treatment of multiple myeloma DL Hermanson, BE Barnett, S Rengarajan, R Codde, X Wang, Y Tan, ... Blood 128 (22), 2127, 2016 | 29 | 2016 |
| Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells BB Madison, D Patil, M Richter, X Li, M Tong, S Cranert, X Wang, R Martin, ... Molecular Therapy-Nucleic Acids 29, 979-995, 2022 | 28 | 2022 |
| piggyBacTM-produced CAR-T cells exhibit stem-cell memory phenotype BE Barnett, DL Hermanson, JB Smith, X Wang, Y Tan, CE Martin, ... Blood 128 (22), 2167, 2016 | 24 | 2016 |
| Manufacture of an allogeneic CAR-T stem cell memory product candidate for multiple myeloma, P-Bcma-ALLO1, is robust, reproducible and highly scalable SA Cranert, M Richter, M Tong, L Weiss, Y Tan, EM Ostertag, J Coronella, ... Blood 134, 4445, 2019 | 10 | 2019 |
| B-Cell Maturation Antigen (BCMA)-Specific, CentyrinTM-Based, PiggyBacTM-Transposed CAR-T Memory Stem Cells Are Effective Against p53-/- and Patient … R Mathur, BE Barnett, D Hermanson, J He, Z Zhang, S Rengarajan, ... Blood, The Journal of the American Society of Hematology 130 (Suppl_1), 3068 …, 2017 | 8 | 2017 |
| P-Muc1c-Allo1: A fully allogeneic stem cell memory T cell (Tscm) car-T therapy with broad potential in solid tumor Y Zhang, A Kozlowska, J Fritz, YY Zhao, CP La Torre, S Cranert, S Wang, ... J Immunother Cancer 9, 2021 | 7 | 2021 |
| Memory phenotype in allogeneic anti-bcma car-T cell therapy (P-Bcma-Allo1) correlates with in vivo tumor control H Tseng, Y Zhang, SA Cranert, M Richter, K Marquez, J Qiu, B Cho, Y Tan, ... Blood 138, 4802, 2021 | 6 | 2021 |
| Production of universal anti-Bcma CAR-T cells with reduced alloreactivity, but potent effector function for the treatment of multiple myeloma X Wang, BE Barnett, C Martin, D Hermanson, X Li, J Smith, J Wu, ... Blood 130, 503, 2017 | 5 | 2017 |
| Development of novel non-immunoglobulin centyrin-based cars (CARTyrins) targeting human Bcma BE Barnett, X Wang, DL Hermanson, Y Tan, EM Osertag, DJ Shedlock Blood 128 (22), 4557, 2016 | 5 | 2016 |
| PiggyBac-manufactured anti-BCMA Centyrin-based CAR-T therapeutic exhibits improved potency and durability D Hermanson, BE Barnett, S Rengarajan, R Codde, CE Martin, X Wang, ... Cancer Research 77 (13_Supplement), 3759-3759, 2017 | 4 | 2017 |
| 120 P-MUC1C-ALLO1: An allogeneic car-t for multiple solid tumor indications A Kozlowska, Y Zhang, J Fritz, S Wang, R Codde, E Argus, S Ibitokou, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 3 | 2020 |
| Cas-CLOVER™: A high-fidelity genome editing system for safe and efficient modification of cells for immunotherapy X Li, X Wang, M Tong, Y Tan, JD Down, DJ Shedlock, EM Ostertag 2018 Precision CRISPR Congress Poster Presentation, Boston, MA, 2018 | 3 | 2018 |
| Abstract A071: PSMA-specific CARTyrin T-stem cell memory therapy eliminates solid tumor in subcutaneous prostate cancer model JB Smith, R Codde, Y Tan, BE Barnett, D Hermanson, S Rengarajan, ... Cancer Research 78 (16_Supplement), A071-A071, 2018 | 2 | 2018 |
| High-fidelity genome editing using NextGEN CRISPR (Clo51-dCas9) system for the production of allogeneic CAR-T cells. X Wang, X Li, B Barnett, C Martin, D Hermanson, J Smith, S Rengarajan, ... Journal of Clinical Oncology 35 (15_suppl), 3048-3048, 2017 | 2 | 2017 |
| P-BCMA-ALLO1-a fully allogeneic stem cell memory T cell (T-SCM) CAR-T therapy targeting BCMA for the treatment of multiple myeloma shows potent anti-tumor activity M Richter, S Cranert, D Patil, Y Zhang, Y Tan, M Tong, C Domingo, ... MOLECULAR THERAPY 29 (4), 382-383, 2021 | 1 | 2021 |
| Robust, reproducible and highly scalable manufacturing of P-BCMA-ALLO1, an allogeneic CAR-T stem cell memory product for multiple myeloma, from numerous healthy donors S Cranert, M Richter, M Tong, L Weiss, Y Tan, E Ostertag, J Coronella, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 7, 2019 | 1 | 2019 |
| P-BCMA-ALLO1-a nonviral, allogeneic anti-BCMA CAR-T therapy with potent antitumor function for the treatment of multiple myeloma M Richter, S Cranert, YN Tan, M Tong, C Domingo, E Argus, SA Ibitokou, ... J IMMUNOTHER CANCER 7, O7, 2019 | 1 | 2019 |
| PSMA-specific CARTyrin T-stem cell memory therapy eliminates solid tumor in subcutaneous prostate cancer model. JB Smith, R Codde, Y Tan, BE Barnett, D Hermanson, S Rengarajan, ... CANCER RESEARCH 78 (16), 63-63, 2018 | 1 | 2018 |
| The Application of ‘Drug-Reversible’CAR-T Cells Directed Against Recipient Hematopoietic Cells As a Selective Conditioning Strategy for Stem Cell Transplantation N Timberlake, M Richter, X Wang, N Cam, Y Tan, EM Ostertag, ... Blood 130, 1893, 2017 | 1 | 2017 |
| A Novel Booster Molecule Improves the Manufacture of TCR Gene-Edited Allogeneic CAR-T Therapies D Shedlock, M Richter, S Cranert, M Tong, Y Tan, R Codde, L Weiss, ... MOLECULAR THERAPY 29 (4), 373-374, 2021 | | 2021 |
